|
Name |
Allyl valerate
|
Molecular Formula | C8H14O2 | |
IUPAC Name* |
prop-2-enyl pentanoate
|
|
SMILES |
CCCCC(=O)OCC=C
|
|
InChI |
InChI=1S/C8H14O2/c1-3-5-6-8(9)10-7-4-2/h4H,2-3,5-7H2,1H3
|
|
InChIKey |
PWYXVVREDGESBB-UHFFFAOYSA-N
|
|
Synonyms |
Allyl valerate; 6321-45-5; Allyl pentanoate; prop-2-enyl pentanoate; allyl n-valerate; Pentanoic acid, 2-propenyl ester; Valeric acid allyl ester; prop-2-en-1-yl pentanoate; YZV641464H; NSC-32631; ALLYLN-VALERATE; allylvalerat; UNII-YZV641464H; Allyl pentanoate #; EINECS 228-675-9; ALLYL VALERATE [FHFI]; SCHEMBL437266; FEMA NO. 4074; DTXSID70212577; CHEBI:180290; NSC32631; ZINC1665012; LMFA07010781; MFCD00078336; NSC 32631; PENTANOIC ACID 2-PROPENYL ESTER; FT-0767086; Q27294812
|
|
CAS | 6321-45-5 | |
PubChem CID | 80606 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 142.2 | ALogp: | 2.1 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 10 | QED Weighted: | 0.435 |
Caco-2 Permeability: | -4.259 | MDCK Permeability: | 0.00003790 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.069 |
30% Bioavailability (F30%): | 0.527 |
Blood-Brain-Barrier Penetration (BBB): | 0.999 | Plasma Protein Binding (PPB): | 69.26% |
Volume Distribution (VD): | 0.781 | Fu: | 46.56% |
CYP1A2-inhibitor: | 0.924 | CYP1A2-substrate: | 0.333 |
CYP2C19-inhibitor: | 0.444 | CYP2C19-substrate: | 0.627 |
CYP2C9-inhibitor: | 0.096 | CYP2C9-substrate: | 0.746 |
CYP2D6-inhibitor: | 0.067 | CYP2D6-substrate: | 0.473 |
CYP3A4-inhibitor: | 0.158 | CYP3A4-substrate: | 0.264 |
Clearance (CL): | 11.425 | Half-life (T1/2): | 0.897 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.054 |
Drug-inuced Liver Injury (DILI): | 0.046 | AMES Toxicity: | 0.144 |
Rat Oral Acute Toxicity: | 0.885 | Maximum Recommended Daily Dose: | 0.029 |
Skin Sensitization: | 0.807 | Carcinogencity: | 0.596 |
Eye Corrosion: | 0.932 | Eye Irritation: | 0.98 |
Respiratory Toxicity: | 0.174 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000371 | 0.594 | D0AY9Q | 0.327 | ||||
ENC000718 | 0.475 | D01QLH | 0.289 | ||||
ENC000655 | 0.463 | D0Z5BC | 0.260 | ||||
ENC000245 | 0.459 | D0Y3KG | 0.233 | ||||
ENC000235 | 0.457 | D0OL6O | 0.233 | ||||
ENC000228 | 0.439 | D0Y4AW | 0.222 | ||||
ENC000226 | 0.412 | D02HXS | 0.220 | ||||
ENC000232 | 0.412 | D0R3QY | 0.220 | ||||
ENC000758 | 0.400 | D0G2KD | 0.219 | ||||
ENC001253 | 0.400 | D0EP8X | 0.216 |